Trial Profile

Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial HoT-PE

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary)
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Adverse reactions; Therapeutic Use
Acronyms HoT-PE

16 Nov 2021 This trial is completed in Portugal (End Date: 26 Nov 2019), according to European Clinical Trials Database record.
22 Oct 2020 This trial is completed in Netherland (Global End Date: 26 Nov 2019), according to European Clinical Trials Database record.
28 Aug 2020 Results (N=576), assessing long-term survival as well as the quality of life and its change over time following early discharge of patients with acute low-risk pulmonary embolism, published in the European Respiratory Journal

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com